Diovan Hct
Product Images NDC 68258-6056

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Diovan Hct (NDC 68258-6056). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Dispensing Solutions, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Ndc 68258-6056-xx (Ndc 68258 6056 Xx Norvatis)

Label for Diovan HCT 80 mg/12.5 mg tablets from Dispensing Solutions, Inc. The label includes product NDC 68258-6056-XX and states each tablet contains 80 mg valsartan and 12.5 mg hydrochlorothiazide. Additional information includes a warning about use during pregnancy, dosage instructions, and distributor details from Novartis Pharmaceuticals Corporation.*

FDA Label Image

Figure 1: Probability Of Achieving Systolic Blood Pressure <140 Mmhg At Week 8 (Diovan Hct 01)

A line graph comparing the percent reduction in systolic blood pressure (SBP) from baseline values between Diovan HCT 320/25 mg, Valsartan 320 mg, and Hydrochlorothiazide 25 mg. The x-axis represents baseline SBP in mmHg (140 to 180), and the y-axis shows the percentage of SBP reduction (0% to 100%). Different markers distinguish each treatment group.*

FDA Label Image

Figure 2: Probability Of Achieving Diastolic Blood Pressure <90 Mmhg At Week 8 (Diovan Hct 02)

Clinical response graph showing baseline diastolic blood pressure (DBP) on the x-axis versus change in DBP on the y-axis for Diovan HCT 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and placebo. The chart compares the blood pressure-lowering effects of these treatments.*

FDA Label Image

Figure 3: Probability Of Achieving Systolic Blood Pressure <130 Mmhg At Week 8 (Diovan Hct 03)

A line graph showing the percentage of systolic blood pressure (SBP) less than 140 mmHg as a function of baseline SBP (mmHg). The graph compares four groups: Diovan HCT 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and Placebo, each represented by different markers. The data illustrates the efficacy trends of these treatments across baseline SBP values.*

FDA Label Image

Figure 4: Probability Of Achieving Diastolic Blood Pressure <80 Mmhg At Week 8 (Diovan Hct 04)

A line graph depicting the percentage reduction in Diastolic Blood Pressure (DBP) from baseline values in mmHg, comparing Diovan HCT 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and Placebo treatments. The x-axis shows baseline DBP values ranging from 90 to 110 mmHg, and the y-axis shows the percent DBP reduction from 0 to 100%.*

FDA Label Image

Valsartan Structural Formula (Diovan Hct 05)

Chemical structure of the active ingredient shown for Diovan HCT, illustrating the molecular arrangement with carbon, hydrogen, nitrogen, and oxygen atoms typical of this pharmaceutical compound.*

FDA Label Image

Hydrochlorothiazide Structural Formula (Diovan Hct 06)

Chemical structure of the active ingredient in Diovan HCT, showing a benzene ring with attached chlorine, sulfonamide, and amine functional groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.